Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INZYNASDAQ:IZTCNASDAQ:NGNENASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINZYInozyme Pharma$4.00+0.3%$2.85$0.72▼$6.24$257.60M2.29896,651 shs386,435 shsIZTCInvizyne Technologies$10.24-0.8%$12.68$8.50▼$23.00$64.02MN/A37,647 shs5,085 shsNGNENeurogene$16.57-1.8%$17.23$6.88▼$74.49$240.74M1.57249,282 shs117,117 shsTNXPTonix Pharmaceuticals$35.54+4.6%$28.20$6.76▼$130.00$250.07M2.09935,091 shs522,243 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINZYInozyme Pharma+0.25%+0.50%+1.27%+334.78%-9.50%IZTCInvizyne Technologies-0.78%-20.06%-31.28%+1.09%+1,023,999,900.00%NGNENeurogene-1.84%-9.45%-3.04%+14.12%-48.23%TNXPTonix Pharmaceuticals+4.56%+3.55%-3.92%+76.20%-68.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINZYInozyme Pharma3.2199 of 5 stars4.23.00.00.02.62.50.0IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ANGNENeurogene3.6682 of 5 stars4.43.00.00.01.62.51.3TNXPTonix Pharmaceuticals2.9347 of 5 stars3.52.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINZYInozyme Pharma 2.44Hold$11.75193.75% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ANGNENeurogene 2.75Moderate Buy$46.17178.62% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,546.03% UpsideCurrent Analyst Ratings BreakdownLatest IZTC, TNXP, INZY, and NGNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.005/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/16/2025NGNENeurogeneBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$38.00 ➝ $24.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ANGNENeurogene$930K254.07N/AN/A$20.89 per share0.79TNXPTonix Pharmaceuticals$10.09M25.92N/AN/A$31.82 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)IZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ANGNENeurogene-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest IZTC, TNXP, INZY, and NGNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINZYInozyme PharmaN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINZYInozyme Pharma0.652.192.19IZTCInvizyne TechnologiesN/AN/AN/ANGNENeurogeneN/A21.0321.03TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINZYInozyme Pharma88.30%IZTCInvizyne TechnologiesN/ANGNENeurogene52.37%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipINZYInozyme Pharma12.18%IZTCInvizyne TechnologiesN/ANGNENeurogene11.64%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableIZTCInvizyne Technologies296.25 millionN/AN/ANGNENeurogene9014.26 million12.60 millionOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableIZTC, TNXP, INZY, and NGNE HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.7% - Still a Buy?June 26 at 2:42 PM | marketbeat.comTonix Pharmaceuticals Holding Corp TNXP Company Vitals - U.S. NewsJune 26 at 10:17 AM | money.usnews.comTNXP - Tonix Pharmaceuticals Holding Corp News - MorningstarJune 26 at 10:17 AM | morningstar.comMTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.3% - Time to Sell?June 25 at 2:20 PM | marketbeat.comRhumbline Advisers Invests $244,000 in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 25 at 3:05 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 5% - What's Next?June 24 at 2:17 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Should You Sell?June 23, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3% - What's Next?June 20, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Here's What HappenedJune 19, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Time to Sell?June 18, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 9.9% Higher - Still a Buy?June 16, 2025 | marketbeat.comTonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A BuyJune 16, 2025 | seekingalpha.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...June 16, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock NewsJune 16, 2025 | gurufocus.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...June 16, 2025 | gurufocus.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025June 16, 2025 | globenewswire.comTwo Sigma Investments LP Makes New $66,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 14, 2025 | marketbeat.comMillennium Management LLC Lowers Holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 14, 2025 | marketbeat.comTonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim” Hunter, to Board of DirectorsJune 13, 2025 | manilatimes.netMTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.8% - Time to Sell?June 13, 2025 | marketbeat.comTonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?June 13, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIZTC, TNXP, INZY, and NGNE Company DescriptionsInozyme Pharma NASDAQ:INZY$4.00 +0.01 (+0.25%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$4.00 0.00 (-0.12%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Invizyne Technologies NASDAQ:IZTC$10.24 -0.08 (-0.78%) As of 06/25/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Neurogene NASDAQ:NGNE$16.57 -0.31 (-1.84%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$16.63 +0.06 (+0.39%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Tonix Pharmaceuticals NASDAQ:TNXP$35.54 +1.55 (+4.56%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$35.50 -0.04 (-0.11%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
